Please check your internet connection and try again.
# Ferrous Ascorbate
## Overview
Ferrous ascorbate is a chelated form of iron consisting of ferrous iron and ascorbic acid (Vitamin C). The inclusion of ascorbic acid acts as a reducing agent, maintaining iron in the ferrous (Fe2+) state, which enhances solubility and iron absorption in the upper gastrointestinal tract compared to traditional ferrous sulfate.
## Primary Indications
Treatment and prevention of iron deficiency anemia (IDA).
## Adult Dosing
* **Standard IDA:** 100 mg (elemental iron) once or twice daily.
* **Maximum Dose:** Generally 200 mg of elemental iron daily, though split dosing may improve tolerance and absorption.
* **Duration:** Therapy should continue for 3–6 months after hemoglobin normalizes to replenish stores.
## Pediatric Dosing
* **Treatment of IDA:** 3–6 mg/kg/day of elemental iron, divided into 1–3 doses.
* **Note:** Dosing varies significantly by local institutional protocols and formulations. Consult specialized pediatric references or institutional guidelines before prescribing.
## Dose Adjustments
* **Renal Impairment:** No specific adjustment required; however, chronic kidney disease (CKD) patients often require intravenous iron due to impaired oral absorption (hepcidin elevation).
* **Hepatic Impairment:** Use with caution in patients with iron overload syndromes or chronic liver disease.
## Contraindications
* Hypersensitivity to any component.
* Hemochromatosis, hemosiderosis, or hemolytic anemias (unless IDA is co-existent).
* Patients receiving repeated blood transfusions.
## Adverse Effects
* **Gastrointestinal (Common):** Epigastric pain, nausea, constipation, diarrhea, and dark-colored stools.
* **Serious:** Potential for GI mucosal irritation or toxicity in overdose; iron overload due to chronic misuse.
## Key Drug Interactions
* **Antacids/H2 Blockers/PPIs:** Reduce absorption; separate administration by at least 2 hours.
* **Fluoroquinolones/Tetracyclines:** Iron chelates with these antibiotics, significantly reducing their efficacy; separate by 2–4 hours.
* **Levothyroxine:** Iron reduces levothyroxine absorption; separate by at least 4 hours.
## Monitoring
* **Baseline:** Complete Blood Count (CBC), serum ferritin, and iron saturation (TSAT).
* **Follow-up:** Reticulocyte count (7–10 days post-initiation); hemoglobin/hematocrit (4 weeks post-initiation).
* **Long-term:** Monitor ferritin levels to confirm repletion of iron stores.
## Clinical Pearls
* **Enhanced Absorption:** Ascorbic acid facilitates iron absorption; therefore, this formulation often produces higher bioavailability and potentially fewer GI side effects than sulfate salts.
* **Timing:** For optimal absorption, take on an empty stomach (1 hour before or 2 hours after meals). If GI upset occurs, administration with food may be necessary, though absorption will be reduced.
* **Stool Changes:** Inform patients that dark or black stools are an expected, harmless side effect of oral iron therapy.
* **Safety:** Iron toxicity is life-threatening in children. Always store in child-resistant containers.
***
**Disclaimer:** This information is for educational purposes only. Clinical dosing and practices vary by region and institutional protocol. Always verify current prescribing information—including patient-specific contraindications, drug interactions, and local guidelines—via authoritative databases (e.g., Lexicomp, Micromedex, or the BNF) before prescribing or administering medication.
